Novartis meningitis vax promising in PhIII

Novartis' meningitis B vaccine, 4CMenB, has turned in promising late-stage data with "an acceptable" safety profile. After testing the drug in more than 3,600 infants, Novartis reported that its researchers tracked a "robust" immune response. A European app is expected by the end of this year. Story